Skip to content

Martin Reck

LungenClinic Grosshansdorf

2 papers in the Anchorcite directory, published between 2015 and 2016, cited 18,827 times in total.

ORCID profile

Research topics

Frequent co-authors

  • Julie Renee Brahmer · 2 papers
  • Delvys Rodríguez‐Abreu · 1 paper
  • Andrew George Robinson · 1 paper
  • Rina Hui · 1 paper
  • Tibor Csőszi · 1 paper
  • Andrea Fülöp · 1 paper
  • Maya Gottfried · 1 paper
  • Nir Peled · 1 paper

Papers

  1. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine · 2016 · 10,276 citations

    BACKGROUND: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). METHODS: In this open-label, phase 3…

  2. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 8,551 citations

    BACKGROUND: Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully human IgG4…

Metadata from OpenAlex (CC0).